Viking Therapeutics, Inc.

NasdaqCM:VKTX 주식 보고서

시가총액: US$5.9b

Viking Therapeutics 관리

관리 기준 확인 2/4

Viking Therapeutics CEO는 Brian Lian, Sep2012 에 임명되었습니다 의 임기는 12.17 년입니다. 총 연간 보상은 $ 12.63M, 4.9% 로 구성됩니다. 4.9% 급여 및 95.1% 보너스(회사 주식 및 옵션 포함). 는 $ 100.41M 가치에 해당하는 회사 주식의 1.71% 직접 소유합니다. 100.41M. 경영진과 이사회의 평균 재임 기간은 각각 5.3 년과 10.5 년입니다.

주요 정보

Brian Lian

최고 경영자

US$12.6m

총 보상

CEO 급여 비율4.9%
CEO 임기12.2yrs
CEO 소유권1.7%
경영진 평균 재임 기간5.3yrs
이사회 평균 재임 기간10.5yrs

최근 관리 업데이트

Recent updates

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Nov 04

Viking Therapeutics: Lots Of Positives

Oct 28

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Sep 25

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Sep 07
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Aug 30

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Jul 25

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Apr 26
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Viking Therapeutics: Future Weight Loss Heavyweight?

Apr 02

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

Jan 09
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Sep 21
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Jun 07
Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Mar 05
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics: Playing Second Fiddle To Madrigal

Aug 30

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Jul 13
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Revisiting Viking Therapeutics

Apr 20

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Apr 12
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Dec 17
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Viking Therapeutics: Remaining Bullish And Sticking To My Plan

Aug 27

Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder

Jun 17

Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Jan 13
Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Viking Therapeutics announces senior management appointments

Jan 06

Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Dec 09
Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Viking Therapeutics: Progressing Steadily, But Concerns Remain

Nov 29

CEO 보상 분석

Brian Lian 의 보수는 Viking Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$99m

Jun 30 2024n/an/a

-US$97m

Mar 31 2024n/an/a

-US$94m

Dec 31 2023US$13mUS$615k

-US$86m

Sep 30 2023n/an/a

-US$81m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$72m

Dec 31 2022US$5mUS$612k

-US$69m

Sep 30 2022n/an/a

-US$62m

Jun 30 2022n/an/a

-US$59m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$4mUS$594k

-US$55m

Sep 30 2021n/an/a

-US$54m

Jun 30 2021n/an/a

-US$50m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$5mUS$577k

-US$39m

Sep 30 2020n/an/a

-US$36m

Jun 30 2020n/an/a

-US$32m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$4mUS$525k

-US$26m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$24m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$1mUS$485k

-US$22m

Sep 30 2018n/an/a

-US$21m

Jun 30 2018n/an/a

-US$20m

Mar 31 2018n/an/a

-US$19m

Dec 31 2017US$805kUS$440k

-US$21m

보상 대 시장: Brian 의 총 보상 ($USD 12.63M )은 US 시장( $USD 7.74M ).

보상과 수익: 회사가 수익성이 없는 동안 Brian 의 보상이 증가했습니다.

CEO

Brian Lian (58 yo)

12.2yrs

테뉴어

US$12,628,061

보상

Dr. Brian Lian, Ph D., served as Director at Apricus Biosciences, Inc. He has been the Chief Executive Officer and President at Viking Therapeutics, Inc. since September 24, 2012. Dr. Lian has been an Inde...

리더십 팀

이름위치테뉴어보상소유권
Brian Lian
President12.2yrsUS$12.63m1.71%
$ 100.4m
Gregory Zante
Chief Financial Officer5.3yrsUS$3.50m0.0010%
$ 60.4k
Marianne Mancini
Chief Operating Officer3.8yrsUS$3.51m0.18%
$ 10.8m
Michael Morneau
Vice President of Finance & Administration6.6yrsUS$619.56k데이터 없음
Geoffrey Barker
Senior Vice President of Pharmaceutical Development1.8yrs데이터 없음데이터 없음

5.3yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 관리: VKTX 의 관리팀은 노련하고 경험 (평균 재직 기간 5.3 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Brian Lian
President12.2yrsUS$12.63m1.71%
$ 100.4m
Scott Hecker
Scientific Advisorno data데이터 없음데이터 없음
Matthew Foehr
Independent Director10.5yrsUS$169.37k0.10%
$ 5.9m
J. Singleton
Independent Director10.5yrsUS$192.77k0.0085%
$ 499.9k
Charles Rowland
Independent Director7.3yrsUS$189.62k0.027%
$ 1.6m
Alan Cherrington
Scientific Advisorno data데이터 없음데이터 없음
G. Alexander Fleming
Scientific Advisorno data데이터 없음데이터 없음
Jay Magaziner
Scientific Advisorno data데이터 없음데이터 없음
David Bullough
Scientific Advisorno data데이터 없음데이터 없음
Lawson MacArtney
Independent Chairman10.5yrsUS$222.72k0.043%
$ 2.5m
Stephan Kemp
Scientific Advisorno data데이터 없음데이터 없음
S. Rouan
Independent Director5.3yrsUS$178.65k0%
$ 0

10.5yrs

평균 재임 기간

63.5yo

평균 연령

경험이 풍부한 이사회: VKTX 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.5 년).